β-blockers in heart failure: recently completed and ongoing clinical trials

Bibliography

• GARG R, PACKER M, PITT B, YUSUF S: Heart failure in the 1990s: evolution of a major public health problem in cardiovascular medicine. J. Am. Coll. Cardiol. (1993) 22 (Suppl):3A–5A.
   Google Scholar
• GHALI JK, COOPER R, FORD E: Trends in hospitalization for heart failure in the United States, 1973-1986: evidence for increasing population prevalence. Arch. Intern. Med. (1990) 150:769–773.
   PubMed Web of Science ®Google Scholar
• NATIONAL HEART, LUNG AND BLOOD INSTITUTE: Morbidity and mortality: 1998 Chartbook on cardio-vascular, lung and blood diseases. NHLBI October (1998).
   Google Scholar
• RICH MW: Therapy for acute myocardial infarction in older persons. J. Am. Geriatr. Soc. (1998) 46:1302–1307.
   PubMed Web of Science ®Google Scholar
• SHARPE N, DOUGHTY R: Epidemiology of heart failure and ventricular dysfunction. Lancet (1998) 352 (Suppl):SI3–S17.
   Google Scholar
• ••Excellent review.
   Google Scholar
• DOUGHTY R, ERSEN V, SHARPE N: Optimal treatment of heart failure in the elderly. Drugs Aging (1997) 10:435–443.
   Google Scholar
• MANN DL: Mechanisms and models in heart failure. A combinatorial approach. Circulation (1999) 100:999–1008.
   PubMed Web of Science ®Google Scholar
• ••Outstanding review.
   Google Scholar
• COHN JN: Structural basis for heart failure: ventricular remodeling and its pharmacological inhibition. Circulation (1995) 91:2504–2507.
   PubMed Web of Science ®Google Scholar
• VASAN RS, LARSON MG, BENJAMIN EJ, EVANS JC, LEVY D: Left ventricular dilation and the risk of congestive heart failure. N Engl. J. Med. (1997) 336:1350–1355.
   PubMed Web of Science ®Google Scholar
• PERONDI R, SAINO A, TIO RA et al. ACE inhibition attenuates sympathetic coronary vasoconstriction in patients with coronary artery disease. Circulation (1992) 85:2004–2013.
   PubMed Web of Science ®Google Scholar
• THE CONSENSUS TRIAL STUDY GROUP: Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl. J. Med. (1987) 316:1429–1435.
   PubMed Web of Science ®Google Scholar
• ••Landmark paper.
   Google Scholar
• THE SOLVD INVESTIGATORS: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl. J. Med (1991) 325:293–302.
   PubMed Web of Science ®Google Scholar
• ••Important findings.
   Google Scholar
• PFEFFER M, BRAUNWALD E, MOYE L et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarc-tion. Results of survival and ventricular enlargement trial. N Engl. J Med. (1992) 327:669–677.
   PubMed Web of Science ®Google Scholar
• ••Important results.
   Google Scholar
• COHN JN, JOHNSON G, ZIESCHE S et al: A comparison of enalapril with hydralazine- isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl. J. Med. (1991) 325:303–310.
   PubMed Web of Science ®Google Scholar
• ••Important result.
   Google Scholar
• PITT B, ZANNAD F, REMME WJ et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl. J. Med (1999) 341:709–717.
   PubMed Web of Science ®Google Scholar
• ••Important paper establishing use of spironolactone.
   Google Scholar
• REICHENBACH DD, BENDITT EP: Catecholamines and cardiomyopathy: the pathogenesis and potential importance of myofibrillar degeneration. Hum. Pathol (1970) 1:125–149.
   Google Scholar
• HAFT JL: Cardiovascular injury induced by sympathetic catecholamines. Prog. Cardiovasc. Dis. (1974) 17:73–85.
   PubMed Web of Science ®Google Scholar
• COHN JN, LEVINE TB, OLIVARI MT et al.: Plasma norepi-nephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl. J. Med. (1984) 311:819–823.
   PubMed Web of Science ®Google Scholar
• WAAGSTEIN F, HJALMARSON A, VARNAUSKAS E, WALLENTIN I: Effect of chronic beta- adrenergic receptor blockade in congestive cardiomyopathy. Br. Heart J. (1975) 37:1022–1036.
   PubMedGoogle Scholar
• SWEDBERG K, HJALMARSON A, WAAGSTEIN F, WALLENTIN I: Adverse effects of beta- blockade withdrawal in patients with congestive cardiomyopa-thy. Br. Heart J. (1980) 44:134–142.
   PubMedGoogle Scholar
• ENGELMEIER RS, O'CONNELL JB, WALSH R, RAD N,SCANLON PJ, GUNNAR RM: Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy; a double-blind, randomized, placebo-controlled trial. Circulation (1985) 72:536–546.
   PubMed Web of Science ®Google Scholar
• HEILBRUNN S, SHAH P, BRISTOW M, VALENTINE H, GINSBURG R, FOWLER M: Increased beta- receptor density and improved response to catecholamine stimulation during long term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation (1989) 79:483–490.
   PubMed Web of Science ®Google Scholar
• WAAGSTEIN F, CAIDAHL K, WALLENTIN I, BERGH C, HJALMARSON A: Long term beta- blockade in dilated cardiomyopathy. Circulation (1989) 80:551–563.
   PubMed Web of Science ®Google Scholar
• GILBERT EM, ANDERSON JL, DEITCHMAN D et al.:Chronic beta-blocker-vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopa-thy; a double-blind, randomized study of bucindolol versus placebo. Am. J. Med. (1990) 88:223–229.
   PubMed Web of Science ®Google Scholar
• EICHHORN EJ, BEDOTTO JB, MALLOY CR et al.: Effect ofbeta-adrenergic blockade on myocardial function and energetics in congestive heart failure: improvements in hemodynamic, contractile and diastolic perform-ance with bucindolol. Circulation (1990) 82:473–483.
   PubMed Web of Science ®Google Scholar
• EICHHORN EJ, HEESCH CM, BARNETT JH et al.: Effect ofmetoprolol on myocardial function and energetics in patients with non-ischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J. Am. Coll. Cardiol. (1994) 24:1310–1320.
   PubMed Web of Science ®Google Scholar
• KENNEDY HL, BARKER A, BROOKS MM et al.: Beta-blocker therapy and mortality in the cardiac arrhythmia suppression trial (CAST). Circulation (1992) 86 (Suppl. I):403 (Abstract).
   Google Scholar
• VANTRIMPONT P, ROULEAU JL, WUN CC et al.: Additivebeneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investi-gators. J. Am. Coll Cardiol (1997) 29:229–236.
   PubMed Web of Science ®Google Scholar
• EXNER DV, DRIES DL, WACLAWIW MA et al.: Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction. J. Am. Coll. Cardiol (1999) 33:916–923.
   PubMed Web of Science ®Google Scholar
• WAAGSTEIN F, BRISTOW MR, SWEDBERG K et al.: Benefi-cial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in dilated cardiomyopa-thy (MDC) trial study group. Lancet (1 9 9 3) 342:1441-1446.
   Google Scholar
• CIBIS INVESTIGATORS AND COMMITTEES: A random-ized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation (1994) 90:1765–1773.
   PubMed Web of Science ®Google Scholar
• •Early 6-blocker trial.
   Google Scholar
• HEIDENREICH PA, LEE TT, MASSIE BM: Effect ofbeta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J. Am. Coll. Cardiol. (1997) 30:27–34.
   PubMed Web of Science ®Google Scholar
• LECHAT P, PACKER M, CHALON S, CUCHERAT M, ARAB T,BOISSEL JP: Clinical effects of beta- adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo- controlled, randomized trials. Circulation (1998) 98:1184–1191.
   PubMed Web of Science ®Google Scholar
• PACKER M, BRISTOW MR, COHN JN et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N. Engl. J. Med. (1996) 334:1349–1355.
   PubMed Web of Science ®Google Scholar
• ••[34-38] combined studies show that 6-blockers affectmortality in heart failure.
   Google Scholar
• COLUCCI WS, PACKER M, BRISTOW MR et al: Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation (1996) 94:2800–2806.
   PubMed Web of Science ®Google Scholar
• •See [34] for annotation.
   Google Scholar
• PACKER M, COLUCCI WS, SACKNER-BERNSTEIN JD et al.: Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE trial. Circulation (1996) 94:2793–2799.
   PubMed Web of Science ®Google Scholar
• •See [34] for annotation.
   Google Scholar
• COHN JN, FOWLER MB, BRISTOW MR et al.: Safety and efficacy of carvedilol in severe heart failure. J. Card. Fail. (1997) 3:173–179.
   PubMedGoogle Scholar
• •See [34] for annotation.
   Google Scholar
• BRISTOW MR, GILBERT EM, ABRAHAM WT et al.: Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation (1996) 94:2807–2816.
   PubMed Web of Science ®Google Scholar
• •See [34] for annotation.
   Google Scholar
• MOYE LA: End-point interpretation in clinical trials:the case for discipline. Controlled Clinical Trials (1999) 20:40–49.
   PubMedGoogle Scholar
• AUSTRALIA-NEW ZEALAND HEART FAILURE RESEARCHCOLLABORATIVE GROUP: Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation (1995) 92:212–218
   PubMed Web of Science ®Google Scholar
• AUSTRALIA-NEW ZEALAND HEART FAILURE RESEARCH COLLABORATIVE GROUP: Randomized, placebo-controlled trial of carvedilol in patients with conges-tive heart failure due to ischaemic heart disease. Lancet (1997) 349:375–80.
   PubMed Web of Science ®Google Scholar
• ••6-blocker trial in ischaemic heart failure.
   Google Scholar
• RICHARDS AM, DOUGHTY R, NICHOLLS MG et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Circulation (1999) 99:786–792.
   PubMed Web of Science ®Google Scholar
• TSUYUKI RT, YUSUF S, ROULEAU JL et al.: Combinationneurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can. J. Cardiol. (1997) 13:1166–1174.
   PubMed Web of Science ®Google Scholar
• YUSUF S, MAGGIONI AP, HELD P, ROULEAU J: Effects ofcandesartan enalapril or their combination on exercise capacity, ventricular function, clinical deterioration and quality of life in heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD). Circulation (1997) 96:2527.
   Web of Science ®Google Scholar
• MCKELVIE RS, YUSUF S, PERICAK D eta].: Comparison ofCandesartan, Enalapril and Their Combination in Congestive Heart Failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study: The RESOLVD Pilot Study Investigators. Circulation (1999) 100:1056–1064.
   Google Scholar
• THE CIBIS-II SCIENTIFIC COMMITTEE: Design of theCardiac Insufficiency Bisoprolol Study II (CIBIS40. Fund. Clin. Pharmacol (1997) 11:38–42.
   Google Scholar
• CIBIS-II INVESTIGATORS AND COMMITTEES: The Cardiac Insufficiency Bisoprolol Study II (CIBIS40: a randomized trial. Lancet (1999) 353:9–13.
   PubMed Web of Science ®Google Scholar
• ••Study shows the efficacy of I3-blocker in heart failure.
   Google Scholar
• THE INTERNATIONAL STEERING COMMITTEE ON BEHALF OF THE MERIT-HF STUDY GROUP: Rationale, design and organization of the metoprolol CR/XL randomized trial in heart failure (MERIT-HF). Am. C ardiol (1997) 80:54–581
   Google Scholar
• MERIT-HF STUDY GROUP: Effect of metoprolol CR/X1, in chronic heart failure; Metoprolol CR/XL Random-ized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet (1999) 353: 2001-2007.
   Google Scholar
• ••See [46] for annotation.
   Google Scholar
• THE BEST STEERING COMMITTEE: Design of the beta-blocker evaluation survival trial. Am. J. Cardiol. (1995) 75:1220–1223.
   PubMed Web of Science ®Google Scholar
• EICHORN E, DOMANSKI MJ AND THE BEST INVESTIGA-TORS: BEST. Beta-blocker evaluation survival trial. Presented at the American Heart Association. Atlanta, US November (1999)
   Google Scholar
• RAVIELE A, BONGIORNI MG, BRIGNOLE M et al: Whichstrategy is 'best' after myocardial infarction? The Beta-blocker Strategy plus ImplanTable Cardioverter Defibrillator Trial: rationale and study design. Am. J. Cardiol. (1999) 83:104D–111D.
   Google Scholar
• BOHLER S, SAUBADU S, SCHELDEWAERT R, FIGULLA H-R: Betaxolol versus carvedilol in chronic heart failure (BETACAR study). Arzneim.-Forsch/Drug Res. (1999) 49(0311–317.
   PubMed Web of Science ®Google Scholar
• SACKNER-BERNSTEIN JD: Use of carvedilol in chronic heart failure: challenges in therapeutic management. Frog. Cardiovasc. Dis. (1998) 41 (Suppl. 1):53–58.
   Google Scholar
• •Review of the use of I3-blockers in heart failure.
   Google Scholar
• SAXON LA, BOEHMER JP, HUMMEL J et al.: Biventricular pacing in patients with congestive heart failure: two prospective randomized trials. Am. J. Cardiol (1999) 83:120D–23D.
   Google Scholar
• •Investigations into novel therapy in heart failure.
   Google Scholar
• AURICCHIO A, STELLBRINK C, SACK S et al. The pacing therapies for congestive heart failure (PATH-CHF) study: rationale, design and endpoints of a prospective randomized multicenter study. Am. J. Cardiol. (1999) 83:130D–135D.
   Google Scholar
• •See [55] for annotation.
   Google Scholar
• DAUBERT C, LINDE C, CAZEAU S et al: Protocol design of the MUSTIC (Multisite Stimulation in Cardiomyopa-thy) study. Arch. Mal Coeur Vaiss (1998) 91:154 (Abstract).
   Google Scholar
• •See [55] for annotation.
   Google Scholar
• KLEIN H, AURICCHIO A, REEKS, GELLER C: New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II. Am. J. Cardiol (1999) 83:91D–97D.
   Google Scholar
• •Review of defibrillation therapy and trials in heart failure.
   Google Scholar